A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

• Status: Terminated
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline therapy is not indicated

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Capecitabine; Sunitinib

Criteria

Inclusion Criteria:

• breast adenocarcinoma

• prior treatment with an anthracycline and a taxane either concurrently or sequentially in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than 1 chemotherapy regimen in the advanced setting

Exclusion Criteria:

• Prior treatment with regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/ taxanes treatments.

• Any prior regimen with capecitabine